Posted by Michael Wonder on 15 Jun 2021
Amylyx Pharmaceuticals files new drug submission for AMX0035 for the treatment of ALS in Canada
14 June 2021 - Submission supported by data from the CENTAUR trial.
Amylyx Pharmaceuticals today announced it has submitted a new drug submission to Health Canada for AMX0035 (sodium phenylbutyrate-taurursodiol (TURSO)) for the treatment of ALS.
